FierceBiotech15h
Biogen enlists Royalty for pursuit of lupus crown, securing $250M to fund phase 3 program
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
lupus.bmj8h
Time trends of variability in disease activity in systemic lupus erythematosus
Objective Disease activity both between and within patients with SLE is highly variable, yet factors driving this variability remain unclear. This study aimed to identify predictors of variability in ...
lupus.bmj8h
Long-term safety and efficacy of the combination of belimumab and rituximab in the treatment of severe and refractory SLE: a preliminary report
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
BMJ13h
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring ...